Properties of gravitoturbulent accretion disks

We explore the properties of cold gravitoturbulent accretion disks - non-fragmenting disks hovering on the verge of gravitational instability - using a realistic prescription for the effective viscosity caused by gravitational torques. This prescription is based on a direct relationship between the angular momentum transport in a thin accretion disk and the disk cooling in a steady state. Assuming that opacity is dominated by dust we are able to self-consistently derive disk properties for a given $\dot M$ assuming marginal gravitational stability. We also allow external irradiation of the disk and account for a non-zero background viscosity which can be due to the MRI. Spatial transitions between different co-existing disk states (e.g. between irradiated and self-luminous or between gravitoturbulent and viscous) are described and the location of the boundary at which disk must fragment is determined in a variety of situations. We demonstrate in particular that at low enough $\dot M$ external irradiation stabilizes gravitoturbulent disk against fragmentation all the way to infinity thus providing means of steady mass transport to the central object. Implications of our results for the possibility of planet formation by gravitational instability in protoplanetary disks and star formation in the Galactic Center and for the problem of feeding supermassive black holes in galactic nuclei are discussed.Comment: 12 pages, 3 figures, submitted to Ap

High purity semi-insulating 4H-SiC epitaxial layers by Defect-Competition Epitaxy

Thick, high-purity semi-insulating (SI)homoepitaxial layers on Si-face 4H-SiC weregrownsystematically, with resistivity \geq 109{\Omega}-cmby maintaining high C/Si ratios 1.3-15 during growth.Comparison of secondary ion mass spectra betweenlow-dopedepilayers grown at C/Si ratio<1.3andSI-epilayers grown at C/Si ratio>1.3 showed little difference in residual impurity concentrations. A reconciliation of impurity concentration with measured resistivity indicated a compensating trap concentration of ~1015cm-3present only in the SI-epilayers. High- resolution photo induced transient spectroscopy (HRPITS) identified themas Si-vacancy related deep centers, with no detectable EH6/7 and Z1/2levels. Recombination lifetimes ~5ns suggest application in fast-switching power devices.Comment: Submitted to Applied Physics Letter

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

Background: The EMPA KIDNEY trial showed that empagliflozin reduced the risk of the primary composite outcome of kidney disease progression or cardiovascular death in patients with chronic kidney disease mainly through slowing progression. We aimed to assess how effects of empagliflozin might differ by primary kidney disease across its broad population. Methods: EMPA-KIDNEY, a randomised, controlled, phase 3 trial, was conducted at 241 centres in eight countries (Canada, China, Germany, Italy, Japan, Malaysia, the UK, and the USA). Patients were eligible if their estimated glomerular filtration rate (eGFR) was 20 to less than 45 mL/min per 1·73 m2, or 45 to less than 90 mL/min per 1·73 m2 with a urinary albumin-to-creatinine ratio (uACR) of 200 mg/g or higher at screening. They were randomly assigned (1:1) to 10 mg oral empagliflozin once daily or matching placebo. Effects on kidney disease progression (defined as a sustained ≥40% eGFR decline from randomisation, end-stage kidney disease, a sustained eGFR below 10 mL/min per 1·73 m2, or death from kidney failure) were assessed using prespecified Cox models, and eGFR slope analyses used shared parameter models. Subgroup comparisons were performed by including relevant interaction terms in models. EMPA-KIDNEY is registered with ClinicalTrials.gov, NCT03594110. Findings: Between May 15, 2019, and April 16, 2021, 6609 participants were randomly assigned and followed up for a median of 2·0 years (IQR 1·5–2·4). Prespecified subgroupings by primary kidney disease included 2057 (31·1%) participants with diabetic kidney disease, 1669 (25·3%) with glomerular disease, 1445 (21·9%) with hypertensive or renovascular disease, and 1438 (21·8%) with other or unknown causes. Kidney disease progression occurred in 384 (11·6%) of 3304 patients in the empagliflozin group and 504 (15·2%) of 3305 patients in the placebo group (hazard ratio 0·71 [95% CI 0·62–0·81]), with no evidence that the relative effect size varied significantly by primary kidney disease (pheterogeneity=0·62). The between-group difference in chronic eGFR slopes (ie, from 2 months to final follow-up) was 1·37 mL/min per 1·73 m2 per year (95% CI 1·16–1·59), representing a 50% (42–58) reduction in the rate of chronic eGFR decline. This relative effect of empagliflozin on chronic eGFR slope was similar in analyses by different primary kidney diseases, including in explorations by type of glomerular disease and diabetes (p values for heterogeneity all &gt;0·1). Interpretation: In a broad range of patients with chronic kidney disease at risk of progression, including a wide range of non-diabetic causes of chronic kidney disease, empagliflozin reduced risk of kidney disease progression. Relative effect sizes were broadly similar irrespective of the cause of primary kidney disease, suggesting that SGLT2 inhibitors should be part of a standard of care to minimise risk of kidney failure in chronic kidney disease. Funding: Boehringer Ingelheim, Eli Lilly, and UK Medical Research Council

A new class of glycomimetic drugs to prevent free fatty acid-induced endothelial dysfunction

Background: Carbohydrates play a major role in cell signaling in many biological processes. We have developed a set of glycomimetic drugs that mimic the structure of carbohydrates and represent a novel source of therapeutics for endothelial dysfunction, a key initiating factor in cardiovascular complications. Purpose: Our objective was to determine the protective effects of small molecule glycomimetics against free fatty acid­induced endothelial dysfunction, focusing on nitric oxide (NO) and oxidative stress pathways. Methods: Four glycomimetics were synthesized by the stepwise transformation of 2,5­dihydroxybenzoic acid to a range of 2,5­substituted benzoic acid derivatives, incorporating the key sulfate groups to mimic the interactions of heparan sulfate. Endothelial function was assessed using acetylcholine­induced, endotheliumdependent relaxation in mouse thoracic aortic rings using wire myography. Human umbilical vein endothelial cell (HUVEC) behavior was evaluated in the presence or absence of the free fatty acid, palmitate, with or without glycomimetics (1µM). DAF­2 and H2DCF­DA assays were used to determine nitric oxide (NO) and reactive oxygen species (ROS) production, respectively. Lipid peroxidation colorimetric and antioxidant enzyme activity assays were also carried out. RT­PCR and western blotting were utilized to measure Akt, eNOS, Nrf­2, NQO­1 and HO­1 expression. Results: Ex vivo endothelium­dependent relaxation was significantly improved by the glycomimetics under palmitate­induced oxidative stress. In vitro studies showed that the glycomimetics protected HUVECs against the palmitate­induced oxidative stress and enhanced NO production. We demonstrate that the protective effects of pre­incubation with glycomimetics occurred via upregulation of Akt/eNOS signaling, activation of the Nrf2/ARE pathway, and suppression of ROS­induced lipid peroxidation. Conclusion: We have developed a novel set of small molecule glycomimetics that protect against free fatty acidinduced endothelial dysfunction and thus, represent a new category of therapeutic drugs to target endothelial damage, the first line of defense against cardiovascular disease

Note préliminaire sur les gisements d'étain et d'argent en Bolivie

Kozlowski Roman. Note préliminaire sur les gisements d'étain et d'argent en Bolivie. In: Bulletin de la Société française de Minéralogie, volume 44, 6-8, 1921. pp. 128-151

Air Pollutant Intrusion into the Wieliczka Salt Mine

The Wieliczka Salt Mine World Cultural Heritage Site contains many rock salt sculptures that are threatened by water vapor condensation from the mine ventilation air. Gaseous and particulate air pollutant concentrations have been measured both outdoors and within the Wieliczka Salt Mine, along with pollutant deposition fluxes to surfaces within the mine. One purpose of these measurements was to determine whether or not low deliquescence point ionic materials (e.g., NH_4NO_3) are accumulating on surfaces to an extent that would exacerbate the water vapor condensation problems in the mine. It was found that pollutant gases including SO_2 and HNO_3 present in outdoor air are removed rapidly and almost completely from the air within the mine by deposition to surfaces. Sulfur isotope analyses confirm the accumulation of air pollutant-derived sulfur in liquid dripping from surfaces within the mine. Particle deposition onto interior surfaces in the mine is apparent, with resulting soiling of some of those sculptures that have been carved from translucent rock salt. Water accumulation by salt sculpture surfaces was studied both experimentally and by approximate thermo- dynamic calculations. Both approaches suggest that the pollutant deposits on the sculpture surfaces lower the relative humidity (RH) at which a substantial amount of liquid water will accumulate by 1% to several percent. The extraordinarily low SO_2 concentrations within the mine may explain the apparent success of a respiratory sanatorium located deep within the mine